Abbott Laboratories
ABT
$113.61
-$0.51-0.45%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.46B | 11.37B | 11.14B | 10.36B | 10.97B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.46B | 11.37B | 11.14B | 10.36B | 10.97B |
| Cost of Revenue | 4.91B | 5.08B | 4.85B | 4.46B | 4.88B |
| Gross Profit | 6.55B | 6.29B | 6.29B | 5.90B | 6.09B |
| SG&A Expenses | 4.11B | 2.90B | 2.95B | 2.91B | 3.81B |
| Depreciation & Amortization | 422.00M | 420.00M | 420.00M | 420.00M | 465.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.16B | 9.16B | 8.94B | 8.48B | 9.88B |
| Operating Income | 1.30B | 2.21B | 2.20B | 1.87B | 1.09B |
| Income Before Tax | 2.36B | 2.18B | 2.15B | 1.78B | 2.03B |
| Income Tax Expenses | 582.00M | 536.00M | 371.00M | 453.00M | -7.20B |
| Earnings from Continuing Operations | 1.78B | 1.64B | 1.78B | 1.33B | 9.23B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.78B | 1.64B | 1.78B | 1.33B | 9.23B |
| EBIT | 1.30B | 2.21B | 2.20B | 1.87B | 1.09B |
| EBITDA | 2.09B | 3.00B | 2.98B | 2.63B | 1.90B |
| EPS Basic | 1.00 | 0.94 | 1.02 | 0.76 | 5.28 |
| Normalized Basic EPS | 0.87 | 0.78 | 0.77 | 0.65 | 0.77 |
| EPS Diluted | 1.00 | 0.94 | 1.01 | 0.76 | 5.26 |
| Normalized Diluted EPS | 0.87 | 0.78 | 0.77 | 0.65 | 0.77 |
| Average Basic Shares Outstanding | 1.75B | 1.74B | 1.74B | 1.74B | 1.75B |
| Average Diluted Shares Outstanding | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B |
| Dividend Per Share | 0.63 | 0.59 | 0.59 | 0.59 | 0.59 |
| Payout Ratio | 58.00% | 62.71% | 57.84% | 77.43% | 10.38% |